• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Development of an innovative biomarker for muscle cell damage

Research Project

Project/Area Number 18K07516
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 52020:Neurology-related
Research InstitutionKawasaki Medical School

Principal Investigator

Sunada Yoshihide  川崎医科大学, 医学部, 教授 (00240713)

Co-Investigator(Kenkyū-buntansha) 西松 伸一郎  川崎医科大学, 医学部, 准教授 (20222185)
藤野 雅広  川崎医療福祉大学, 医療技術学部, 講師 (50633856)
Project Period (FY) 2018-04-01 – 2021-03-31
Project Status Completed (Fiscal Year 2020)
Budget Amount *help
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2019: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2018: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Keywords筋疾患 / 筋ジストロフィー / 心疾患 / 急性心筋梗塞 / バイオマーカー
Outline of Final Research Achievements

In this study, we aimed to obtain clinical POC of an novel biomarker for muscle and heart diseases. We discovered that a sarcolemma protein X emerges in peripheral blood from patients with muscle and heart diseases. Surprisingly, X appears at the hyperacute period of myocardial infarction and then disappeared rapidly. We raised antibodies against three different epitopes of X, respectively. We optimized the recognition antibody and the capture antibody for ELISA assay quantifying X. By immunoprecipitation using an antibody, we obtain several types of X binding proteins in blood samples from patients with hyperacute myocardial infarction. We are now investigating mechanisms by which X appears in blood. We will determine which muscle and heart diseases have high diagnostic value by measuring X, and conduct a clinical performance tests for obtaining clinical POC of analytical validity and clinical usefulness.

Academic Significance and Societal Importance of the Research Achievements

筋疾患と心疾患の迅速診断は、治療選択と予後に重要な情報を提供する。とりわけ心筋梗塞の迅速診断は生命予後を左右する。従来のバイオマーカー血清クレアチニンキナーゼ(CK)は筋疾患・心疾患特異性が低く心筋梗塞発症時には直ちにCKが上昇せず、その時間差は生命予後の障壁となる。この障壁を克服するため、鋭敏かつ簡便な筋疾患・心疾患の革新的血中バイオマーカーの開発が待望されている。筋鞘膜蛋白質Xは、心筋梗塞超急性期に上昇・ピークを迎え、その後急速に消退する血中動態からは、CKや従来のマーカーに卓越する心筋梗塞超急性期診断薬として期待できる。

Report

(3 results)
  • 2020 Annual Research Report   Final Research Report ( PDF )
  • 2019 Research-status Report
  • Research Products

    (4 results)

All 2020 2019

All Presentation (2 results) (of which Invited: 1 results) Book (2 results)

  • [Presentation] ドラックリポジショニング医師主導治験による薬事承認: タウリン大量投与はMELAS脳卒中様発作再発を防止する2019

    • Author(s)
      砂田芳秀, 大澤 裕, 西松伸一郎, 萩原宏毅, 後藤雄一, 太田成男
    • Organizer
      日本筋学会第5回学術集会
    • Related Report
      2019 Research-status Report
    • Invited
  • [Presentation] マイオスタチン阻害ペプチドによる筋ジストロフィー治療の基盤研究2019

    • Author(s)
      大澤 裕, 深井雄太, 丹田和恵, 藤野雅広, 西松伸一郎, 砂田芳秀
    • Organizer
      日本筋学会第5回学術集会
    • Related Report
      2019 Research-status Report
  • [Book] 今日の治療指針 2020年版 私はこう治療している2020

    • Author(s)
      砂田芳秀
    • Total Pages
      2192
    • Publisher
      株式会社医学書院
    • ISBN
      9784260039406
    • Related Report
      2020 Annual Research Report
  • [Book] 今日の治療指針 2019年版 私はこう治療している2019

    • Author(s)
      砂田芳秀
    • Total Pages
      2160
    • Publisher
      医学書院
    • ISBN
      9784260036504
    • Related Report
      2019 Research-status Report

URL: 

Published: 2018-04-23   Modified: 2022-01-27  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi